The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases
Cognitive retraining for organizational impairment in obsessive-compulsive disorder
Disclosures: Sadatsugu Sakane: Nothing to Disclose, Hiroaki Fuji: Nothing to Disclose, Animesh Singh: Nothing to Disclose, Hyun Young Kim: Nothing to Disclose, Mojgan Hosseini: Nothing to Disclose, Yusuke Kimura: Nothing to Disclose, Raquel Weber: Nothing to Disclose, Wonseok Lee: Nothing to Disclose, Kanani Hokutan: Nothing to Disclose, Souradipta Ganguly: Nothing to Disclose, Karin Diggle: Nothing to Disclose, Xiao Liu: Nothing to Disclose, Debanjan Dhar: Nothing to Disclose, Linda Burkly Burkly: Editas Medicine: Employee, David Brenner: Nothing to Disclose, Tatiana Kisseleva: Nothing to Disclose 1990 PRECLINICAL PROOF OF CONCEPT OF SAFETY AND EFFICACY FOR RTX001, A NOVEL AUTOLOGOUS MACROPHAGE CELL THERAPY PRODUCT FOR END-STAGE LIVER DISEASE Moony Su 1 Olivia Matthews 1 Mark Cant 1 Anna Hoy 1 Niya Aleksieva 1 Rachel Lopera 1 Philip Starkey Lewis 1 Alejandro Armesilla-Diaz 1 Keith Sutton 1 Kayleigh Thirlwell 1 Lara Campana 1 , 1 Resolution Therapeutics Background: Patients with end-stage liver disease (ESLD) have extensive fibrosis and inflammation, which cause loss of organ function, resulting in decompensation events and limited life expectancy
Los beneficios ms estudiados incluyen mejoras en la fuerza, la potencia, el rendimiento deportivo y la capacidad para realizar trabajo muscular de alta intensidad , aspectos especialmente valorados por deportistas y personas que entrenan regularmente
